Introduction
Enterococci are important nosocomial pathogens, and multi-and vancomycin-resistant isolates of E. faecalis and E. faecium are of special concern in the health care setting. Altogether, 8 genotypes of acquired vancomycin resistance are known in Enterococcus spp. worldwide, but only vanA and vanB are clinically relevant genotypes (Werner 2012) . VanA-type resistance is induced by all glycopeptides and, consequently and by definition, confers resistance to vancomycin and teicoplanin. The VanB type is characterised by susceptibility to teicoplanin (no inducer) and to varying levels of vancomycin resistance expression. However, glycopeptide resistance expression in wild-type strains may vary and MIC values are ambiguous and do not allow a proper determination of the corresponding genotype based on phenotypic test results. For example, vanA genotype vancomycin-resistant enterococci (VRE) exhibiting a VanB (VanD) phenotype, i.e., showing susceptible or intermediate MICs for teicoplanin, are documented worldwide ( Gu et al., 2009 , Henrique et al., 2008 , Park et al., 2008 and Song et al., 2006 . In addition, diagnostics of vanB type strains is challenged by varying expression levels of vancomycin resistance resulting in a wide range of MICs to vancomycin from ≤ 1 to > 256 mg/L including concentrations that are defined as susceptible (≤ 4 mg/L) ( Courvalin, 2006 and Depardieu et al., 2007) . Expression levels do not correlate with the presence of different vanB allele types vanB1 to vanB3. All 3 subtypes are detected by molecular tests and vanB2 is the most prevalent ( Courvalin, 2006 and Werner et al., 2008) . Detection of vanB type resistance by molecular methods circumvents the complications mentioned above with respect to a phenotypical measurement of resistance gene expression but conflicts with prevalence of vanB among nonenterococcal, intestinal colonizers ( Ballard et al., 2005 , Domingo et al., 2005 and Graham et al., 2008 . The vanB gene prevalence in nonenterococcal, intestinal colonizers did not show a geographical preference and appeared at similar rates in different parts of the world as deduced from a number of clinical studies using real-time polymerase chain reaction (PCR)-based screening assays (Bourdon et al., 2010 , Stamper et al., 2007 , Usacheva et al., 2010 , Werner et al., 2011b and Young et al., 2007 .
The problem of varying resistance gene expressions in VanB strains has been a matter of concern for a long time with regard to the proper identification of relevant strains (Jett et al., 1996 and Tenover et al., 1995) . The supposed low overall prevalence of VanB resistance among clinical enterococci worldwide led to a comparably low recognition of this diagnostic problem until now. If and to what extent low-level vanB-type vancomycin resistance expression is clinically relevant could only be estimated from the few studies available so far. The described low-level resistance phenotype is linked to a weak induction of the resistance gene expression via the 2-component regulatory system VanR BVanS B . Inappropriate treatment by glycopeptides led to a selection of constitutively vancomycin-and teicoplanin-resistant vanB strains in vitro (Depardieu et al., 2003) , in an experimental rat endocarditis model (Lefort et al., 2004 ) and under glycopeptide therapy in patients ( Hayden et al., 1993 , Kawalec et al., 2001 and San Millan et al., 2009 , which, as a consequence, caused treatment failures.
The dramatic increase in vanB type prevalence among VRE in a number of European countries ( Bourdon et al., 2011 , Klare et al., 2010 and Soderblom et al., 2010 
Materials and methods

Strain collection
Our laboratory serves as a national focal laboratory for enterococci since the beginning of the 1990s. Diagnostic and university laboratories send strains to us for (vancomycin/teicoplanin) resistance confirmation and molecular typing. Our enterococcal strain collection currently contains > 10,000 isolates, mainly from hospital surveillance and infections, but also from animals, food products, the environment, and stool colonisations in outpatients (Klare et al., 1995a , Klare et al., 1995b , Klare et al., 1999 , Klare et al., 2005 , Werner et al., 2007 , Werner et al., 2010 and Werner et al., 2011a . Until now, we collected and identified 1060 vanB strains including 982 vanB-positive E. faecium and 74 vanB-positive E. faecalis which were all from hospital patients. Of the former, 129 vanB-type E. faecium isolates were selected for this study. They originated from 41 different diagnostic laboratories in Germany (which serve several hospitals), were isolated between 2005 and 2011, and showed different strain characteristics and a vancomycin MIC range of ≤ 1 to > 256 mg/L (determined by an accredited "in-house" method using broth microdilution in cation-adjusted Mueller-Hinton; see below). E. faecium ATCC 19434 and 15 E. faecium vanA/vanB-negative strains were used as negative controls.
Antibiotic susceptibility testing
For all E. faecium isolates, antibiotic susceptibilities were determined as MICs using a broth microdilution method using cation-adjusted Mueller-Hinton broth according to an accredited in-house procedure following the German standards of antimicrobial susceptibility testing (DIN, 2004) . Classification into susceptible/intermediate/resistant (S-I-R) differs between European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical Laboratory Standard Institutes (CLSI) (CLSI, 2011); EUCAST defines MICs for vancomycin with S ≤ 4 mg/L and R > 4 mg/L (no intermediate range) and CLSI defines S ≤ 4 mg/L, I = 8-16 mg/L, and R ≥ 32 mg/L. We used the EUCAST clinical breakpoints when available; for other antibiotics, we applied breakpoints derived from CLSI, DIN, and based on other criteria, e.g., for high-level ciprofloxacin resistance defined as an MIC > 16 mg/L ( Leavis et al., 2006 and Werner et al., 2010) . Strains were classified as resistant with MICs (in milligrams per liter) as follows: penicillin/ampicillin > 8, teicoplanin > 2, erythromycin > 4, linezolid > 4, tetracycline > 4, rifampicin > 0.5, chloramphenicol > 16, tigecycline > 0.5, daptomycin > 4, gentamicin (high-level) > 128, streptomycin (high-level) > 512, quinupristin/dalfopristin > 4. Vancomycin MICs were also assessed by another microdilution method using VITEK® 2 (bioMérieux, Nürtingen, Germany). Samples were handled in a Smart Carrier Station (bioMérieux) and treated as recommended by the manufacturer. The correct inoculum was set using DensiCHECK TM Plus (bioMérieux). Results were assessed as MICs leaving a preadjustment (CLSI, EUCAST, etc.) aside. The Advanced Expert System (AES TM ; bioMérieux) subsequently evaluated the results on the basis of default EUCAST and CLSI ("CLSI global") standards. Etest® for vancomycin was performed according to the recommendation of the manufacturer (bioMérieux). In brief, 2 different protocols were followed: first, a standard method with cation-adjusted Mueller-Hinton agar and an inoculum equivalent to McFarland standard 0.5 and, second, the so-called macromethod using brain heart infusion agar and an inoculum equivalent to McFarland standard 2.0. The latter protocol is suggested by the Etest® manufacturer (bioMérieux) for a confirmation of a supposed vancomycin resistance phenotype. Values are read after incubation at 35 °C for 24 h and again after 48 h (Etest® application sheet for Enterococcus/VRE and vancomycin EAS009). E. faecium ATCC 19434 was used as a control strain. The performance of 3 chromogenic VRE screening agars was evaluated: Oxoid Brilliance TM VRE Agar (Thermo Scientific Fisher, Wesel, Germany), chromID TM VRE (bioMérieux), and CHROMagar TM VRE (Mast Diagnostika, Reinfeld, Germany). Strains were streaked out on selective plates and incubated as recommended by the manufacturers. Growth as single colonies and with equivalent colours was rated as a positive result.
DNA Isolation and PCR
Genomic DNA was prepared using a DNA extraction kit (DNeasy Tissue Kit, Qiagen, Hilden, Germany) according to the manufacturer's instructions. An initial cell wall lysis step was added dissolving the cell pellet in TES buffer (10 mmol/L Tris, 0.5 mmol/L ethylenediaminetetraacetic acid, 10% sucrose [pH 8.0]) plus 10 mg/mL lysozyme (Roche Applied Science, Mannheim, Germany) followed by incubation at 37 °C for 30 min. PCR was performed with a PCR master mix (Fermentas/Thermo Fisher Scientific, St. Leon-Rot, Germany) according to the manufacturer's instructions. Approximately 0.5 μL of isolated genomic DNA (ca. 10 ng) and primers (200 nmol/L each) was added. Amplification of fragments representing the esp, hyl Efm , and vanA/vanB genes was performed in a multiplex PCR as described elsewhere (Werner et al., 2011a) .
Statistics
Statistical analyses were performed with the software package Ridom EpiCompare 1.0 (Ridom; http://www.ridom.de).
Results
Determination of antibiotic susceptibilities
MICs for 15 antibiotics were determined by microbroth dilution in cation-adjusted MH broth as recommended. Distribution of MIC 50 , MIC 90 , and the overall number of resistant strains among 129 vanB VRE isolates is presented in Table 1 . In addition, we assessed the MICs for vancomycin and teicoplanin by an alternative microdilution method in cation-adjusted MH broth as well (VITEK® 2). All isolates were resistant to ampicillin/penicillin and ciprofloxacin (high-level), suggesting the prevalence of vanB resistance genes among hospital-associated clonal types. All 129 vanB strains revealed susceptible MICs for teicoplanin of ≤ 0.5 mg/L (VITEK® 2) and ≤ 1 mg/L (in-house method).
Standard microdilution determined a wide spectrum of vancomycin MICs ranging from ≤ 1 to > 256 mg/L (Fig. 1A) . According to CLSI, only 49% of strains were classified as "resistant" to vancomycin (R ≥ 32 mg/L), and based on EUCAST criteria 86% were classified as vancomycin resistant (R > 4 mg/L); the latter is equivalent to a classification by CLSI combining "intermediate" and "resistant". Resistances to antibiotics of last resort remained rare. Altogether, 17 vanB strains (13%) revealed MICs for vancomycin of ≤ 4 mg/L equivalent to a susceptible range defined by EUCAST and CLSI. The standard Etest® protocol using an inoculum of McFarland standard 0.5 and MH agar detected 21 (16%) after 24 h and 18 (14%) of vanB strains with MICs of ≤ 4 mg/L after 48 h of incubation, respectively (Fig. 1C) . All 15 vanA/vanB-negative E. faecium and the ATCC E. faecium control strain revealed vancomycin Etest® MICs of ≤ 1.5 mg/L (24/48 h), and 13 of them had an identical MIC after 24 and 48 h. In contrast, vanB strains generally showed an elevated 48-h MIC versus the 24-h MIC (Fig. 1C) . Etest® inhibition zones for vanA/vanB-negative E. faecium and the ATCC E. faecium control strain showed a sharp edge of growth inhibition, whereas most vanB strains expressed a specific phenotype with a shady growth at lower vancomycin concentrations ( Fig. 2B and C) , most probably related to the resistance phenotype induced after vancomycin exposure. This zone of weaker growth could span the range from susceptible to resistant MICs (Fig. 2B) . Altogether, 2 vanB E. faecium strains showed microcolonies inside the inhibition zone ("heteroresistance phenotype"), 1 had an MIC of 32 mg/L and the other isolate was initially rated as susceptible with an MIC of 3 mg/L (Fig. 2D) . According to the Etest® application recommendations, these strains should be classified as resistant with MIC > 256 mg/L. Microcolonies taken from inside the inhibition zone, grown overnight on MH agar plates, and tested again for Etest® vancomycin MICs revealed similar phenotypes as assessed before. The modified Etest® macromethod using McFarland 2.0 and BHI agar revealed altogether higher MICs for the 129 vanB E. faecium isolates (Fig. 1D) , confirming the higher sensitivity of this alternative protocol. Altogether, 13 (10%; 24-h incubation) and 7 (5%; 48-h incubation) of the vanB strains showed MICs of ≤ 4 mg/L, respectively. With this protocol, all 15 vanA/vanB-negative E. faecium and the ATCC E. faecium control strain revealed vancomycin Etest® MICs of 3 mg/L after 24 h of incubation and in all but 1 cases an identical value after 48 h (1 isolate had an MIC of 4 mg/L). Six isolates showed microcolony growth inside the Etest inhibition zone, suggesting a heteroresistance phenotype; 5 of them already possessed MICs of > 4 mg/L which would have been classified as resistant anyway (not shown in detail).
Growth on screening agars
We assessed growth of the 129 vanB strains and the 15 vanA/vanB-negative strains on 3 chromogenic VRE agars: Brilliance TM VRE Agar, chromID TM VRE, and CHROMagar TM VRE. Performance was similar on all 3 media (Table 2 ). In general, ≥ 86% of all vanB E. faecium grew on the tested screening agars, 4-5% grew in small colonies only (also rated as positive), and 4-6% did not grow at all. Growth behaviour was not always congruent on all 3 media but isolates that did not grow mainly possessed susceptible MICs as determined by the in-house microdilution, VITEK® 2, and Etest® method. Of the 15 non-vanA/vanB E. faecium strains, 14 did not grow on all media and 1 strain grew on 2 agar plates (Brilliance TM VRE Agar and chromID TM VRE). The susceptible ATCC E. faecium control strain did not grow on all chromogenic media.
Discussion
The numbers of infections and colonizations with vanB type VRE increased in a number of European countries during recent years ( Bourdon et al., 2011 , Klare et al., 2010 and Soderblom et al., 2010 . The supposed growing incidence of vanB type enterococci may have different reasons and could only be partly explained by an increased incidence of vanB type resistant strains. It cannot be excluded that the increased reporting of vanB type resistant enterococci may, at least in part, be attributed to the improved diagnostic capabilities of genotypic assays in targeting the corresponding resistance genes and to the introduction of sensitive chromogenic agar media in diagnosing corresponding vanB type enterococci. In addition, it is not known so far whether the reservoir of vanB resistance genes in nonenterococcal species may feed the resistance gene pool of Enterococcus spp. (Ballard et al., 2005) . The problem of low-level vancomycin resistance expression in vanB type enterococci has been known for a long time but has not been extensively studied or addressed until now, most probably due to its supposed low prevalence and thus moderate clinical significance ( Adler et al., 2010 , Raponi et al., 2010 and Rathe et al., 2010 . The low predictive value for vanB VRE according to the results of VRE screening studies performed in countries of different continents was mainly addressed to the wide prevalence of vanB genes in nonenterococcal, intestinal colonizers ( Rathe et al., 2010 , Stamper et al., 2007 , Usacheva et al., 2010 and Young et al., 2007 . It has to be considered that a substantial number of vanB enterococci may have been missed in previous studies comparing the performance of real-time PCR-based screening assays against phenotypic comparator assays with a supposed low sensitivity in diagnosing vanB VRE with low-level vancomycin resistance expression (Werner et al., 2011b) .
The strains in our study may not represent a common and naïve vanB genotype E. faecium population and thus the investigated strain collection may be biased by the following reasons: all strains were from clinical samples and represented hospital-associated strains of E. faecium (MLST CC17) according to their ampicillin/penicillin and high-level ciprofloxacin resistance phenotypes. In addition, markers only prevalent among hospital strains such as esp and hyl Efm were widely prevalent among the tested 129 isolates (86% and 64%, respectively; not shown in details). Additionally, strains from the present study were preselected in laboratories performing primary diagnostics and sent to us for confirmation and further analysis, a number of them was suspicious in respect of the unsecured or discrepant diagnostic result for VanB when comparing genotypic and phenotypic assay results.
The growth disadvantage of enterococci with an inducible vanB type resistance in MH broth has been described (Jett et al., 1996) , and, correspondingly, several protocols including the Etest® macromethod suggest using rich media (BHI) for VRE confirmation. Thus far, results of our study were in line with results of previous reports; using rich media (BHI instead of MH) and a higher inoculum (McFarland 2.0 instead of 0.5) was also superior here (more sensitive) in identifying vanB type E. faecium strains with a low-level vancomycin resistance expression (Fig. 1C and D) . As a negative control, all 15 vanA/vanB-negative E. faecium and the ATCC E. faecium control strain revealed susceptible vancomycin Etest® MICs of ≤ 4 mg/L (24/48 h). However, the macromethod protocol revealed comparably high values of 3 (4) mg/L near the susceptible breakpoint of ≤ 4 mg/L. It has to be emphasized that, due to unknown reasons, MICs for E. faecalis isolates appear 1-2 twofold dilutions higher than those for E. faecium (not shown) and, consequently, these assumptions are only suitable for vanB type E. faecium.
When comparing vancomycin Etest results on MH agar using the standard protocol to the MIC results of VITEK® 2 (Fig. 1B) and of the in-house DIN protocol (Fig. 1A) , it became obvious that resistance expression is not different on agar and in broth ( Table 2 ). The performance of chromogenic VRE agars was superior to the standard Etest protocol results (24 h) and the MIC assays in liquid broth, but similar to the results of the Etest® macromethod (Table 2) . Nevertheless, these assays have different applications (screening versus MIC determination) and a head-to-head comparison is, maybe, less reasonable.
We describe here for the first time a heteroresistance phenotype for vancomycin for a few VanB isolates. The heteroresistance phenotype has only been described for a clinical vanA VRE and for in vitro-generated descendents of vanA-positive E. faecium strain ATCC 51559 ( Alam et al., 2001 and Khan et al., 2008) . Also, teicoplanin heteroresistance in vanA VRE strains was described recently (Qu et al., 2009) . Several genomic rearrangements and deletions within the vanA gene cluster elements and mutational changes within the 2-component regulator genes vanS and vanR were identified in glycopeptide-heteroresistant strains, but whether these changes were functionally linked to the described heteroresistance phenotype has not been experimentally proven so far. In our hands, the high-level resistant colonies grown inside the inhibition zone were not stable after passage and showed the same phenomenon again.
In conclusion, altogether, 112 vanB-type isolates (87%) were correctly identified as VanB type VRE by both microbroth dilution methods and when using interpretation criteria set as recommended by the manufacturer. The Etest® macromethod protocol using a higher inoculum of McFarland standard 2.0 and 24/48 h of incubation on BHI agar was superior to the standard protocol with McFarland standard 0.5 and MH agar in identifying VanB E. faecium strains while keeping sufficient specificity in correctly diagnosing 15 vanA/vanB-negative test and reference strains. A few vanB isolates showed growth of microcolonies inside the vancomycin inhibition zone, suggesting a VanB heteroresistance phenotype only detectable by Etest® vancomycin. Three commercial chromogenic VRE agars performed similarly with 121 (94%), 123 (95%), and 124 (96%) vanB isolates that grew on Brilliance TM VRE Agar, CHROMagar TM VRE, and chromID TM VRE agar, respectively.
